SKINmed Dermatology for the Clinician · 2006 · 10 citations · 29 references
MedicineDermatologyPathologyDermatopathologyHistopathologySkin Biopsy InterpretationImmunopathology Of SkinInflammatory Skin DiseasesInflammatory Skin DisordersControl Group DesignHistologic ExaminationHistopathologic BiomarkersLaboratory AbnormalitiesMatched Control GroupPsoriasis ImmunopathologyPsoriasis TherapyPsoriatic Disease
OBJECTIVE: The aim of this study was to examine the clinical and histopathologic effects of pentoxifylline on psoriasis, compared with placebo. METHODS: Sixty-one outpatients with active psoriasis were randomly assigned to either of 2 groups: one was given pentoxifylline 400 mg tid PO, and the other, placebo. Fifty-six patients concluded the study. They were evaluated clinically and by laboratory parameters before and after 8 weeks of treatment. Pretreatment and posttreatment biopsies were taken. Initial sections were stained with hematoxylin-eosin. Further cuts were immunostained for cytokeratins 10, 14, and 16. RESULTS: Clinical and histologic improvement did not show statistically significant differences between the groups. No laboratory abnormalities or serious reactions related to the drug were observed. CONCLUSIONS: No statistical difference was seen when the treatment group was compared with the control group. Pentoxifylline is a well tolerated and safe drug, but its efficacy in psoriasis appears to be limited.
29
Fitzpatrick’s Dermatology in General Medicine
Heart & Lung · 1999 · 3.3K citations
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Philip J. Mease, Bernard S. Goffe, James M. Metz et al. · The Lancet · 2000 · 1.5K citations
Lever's Histopathology of the Skin
A. Bernard Ackerman · Archives of Dermatology · 1998 · 1.1K citations